REPORT ID 17980

Global Biosimilars Treatment Market Size, Status and Forecast 2022

Publish Date
03-Oct-17
Pages
102
Format
Electronic (PDF)

This report studies the global Biosimilars Treatment market, analyzes and researches the Biosimilars Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Bayer
    Eli Lily, Inc.
    Pfizer, Inc.
    Sandoz International GmbH
    Teva Pharmaceutical Industries Limited
    Amgen Inc.
    Biocon
    Dr. Reddy's Laboratories
    Roche Ltd.
    Celltrion, Inc.
    Samsung Bioepis

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, Biosimilars Treatment can be split into
    Recombinant Non ? Glycosylated Proteins
    Recombinant Glycosylated Proteins
    Recombinant Peptides

Market segment by Application, Biosimilars Treatment can be split into
    Oncology
    Chronic and Autoimmune Disease
    Blood Disorders
    Growth Hormone Disease
    Infectious Disease

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global Biosimilars Treatment Market Size, Status and Forecast 2022
1 Industry Overview of Biosimilars Treatment
    1.1  Biosimilars Treatment Market Overview
        1.1.1 Biosimilars Treatment Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Biosimilars Treatment Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Biosimilars Treatment Market by Type
        1.3.1 Recombinant Non ? Glycosylated Proteins
        1.3.2 Recombinant Glycosylated Proteins
        1.3.3 Recombinant Peptides
    1.4 Biosimilars Treatment Market by End Users/Application
        1.4.1 Oncology
        1.4.2 Chronic and Autoimmune Disease
        1.4.3 Blood Disorders
        1.4.4 Growth Hormone Disease
        1.4.5 Infectious Disease

2 Global Biosimilars Treatment Competition Analysis by Players
    2.1 Biosimilars Treatment Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Bayer
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Eli Lily, Inc.
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 Pfizer, Inc.
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Sandoz International GmbH
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Teva Pharmaceutical Industries Limited
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 Amgen Inc.
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 Biocon
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Dr. Reddy's Laboratories
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Roche Ltd.
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Celltrion, Inc.
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Biosimilars Treatment Revenue (Value) (2012-2017)
        3.10.5 Recent Developments
    3.11 Samsung Bioepis

4 Global Biosimilars Treatment Market Size by Type and Application (2012-2017)
    4.1 Global Biosimilars Treatment Market Size by Type (2012-2017)
    4.2 Global Biosimilars Treatment Market Size by Application (2012-2017)
    4.3 Potential Application of Biosimilars Treatment in Future
    4.4 Top Consumer/End Users of Biosimilars Treatment

5 United States Biosimilars Treatment Development Status and Outlook
    5.1 United States Biosimilars Treatment Market Size (2012-2017)
    5.2 United States Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

6 EU Biosimilars Treatment Development Status and Outlook
    6.1 EU Biosimilars Treatment Market Size (2012-2017)
    6.2 EU Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

7 Japan Biosimilars Treatment Development Status and Outlook
    7.1 Japan Biosimilars Treatment Market Size (2012-2017)
    7.2 Japan Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

8 China Biosimilars Treatment Development Status and Outlook
    8.1 China Biosimilars Treatment Market Size (2012-2017)
    8.2 China Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

9 India Biosimilars Treatment Development Status and Outlook
    9.1 India Biosimilars Treatment Market Size (2012-2017)
    9.2 India Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Biosimilars Treatment Development Status and Outlook
    10.1 Southeast Asia Biosimilars Treatment Market Size (2012-2017)
    10.2 Southeast Asia Biosimilars Treatment Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Biosimilars Treatment Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Biosimilars Treatment Revenue and Growth Rate (2017-2022)
        11.1.2 EU Biosimilars Treatment Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Biosimilars Treatment Revenue and Growth Rate (2017-2022)
        11.1.4 China Biosimilars Treatment Revenue and Growth Rate (2017-2022)
        11.1.5 India Biosimilars Treatment Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Biosimilars Treatment Revenue and Growth Rate (2017-2022)
    11.2 Global Biosimilars Treatment Market Size (Value) by Type (2017-2022)
    11.3 Global Biosimilars Treatment Market Size by Application (2017-2022)

12 Biosimilars Treatment Market Dynamics
    12.1 Biosimilars Treatment Market Opportunities
    12.2 Biosimilars Treatment Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Biosimilars Treatment Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Biosimilars Treatment Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source